Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Xenios and LEUKOCARE Announce Strategic Partnership

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
LEUKOCARE grants exclusive license on its innovative inflammation inhibition technology and develops a generic coating to be commercialized by Xenios in various extracorporeal therapy systems.

Xenios AG and LEUKOCARE AG, two German based life science companies, have announced a strategic alliance for the development and marketing of Xenios’ extracorporeal support systems with LEUKOCARE’s anti-inflammatory surface coating.

LEUKOCARE has granted to Xenios a worldwide license of its relevant patents and know-how with exclusivity for anti-inflammatory surfaces.

Moreover, Xenios has assigned LEUKOCARE with the adaptation of the clinically proven coating technology to Xenios’ broad range of medical devices that will be commercialized under Novalung, Medos and further Xenios brands.

Anti-inflammatory coatings in Xenios’ medical devices aim to limit unwanted inflammatory responses generated by the artificial device materials to enable improved clinical outcome.

This innovative approach will be facilitated by LEUKOCARE’s proprietary Stabilizing and Protecting Solutions (SPS); these technologies represent a breakthrough in the development of biofunctional surfaces by stabilizing employed proteins, hence allowing terminal sterilization of these combination devices. This results in a higher level of product quality with significantly reduced manufacturing costs compared to aseptic production.

“With LEUKOCARE we have an innovative and ideal strategic partner to develop significantly improved medical devices. The anti-inflammatory function will allow for next generation extracorporeal devices offering tremendous improvement in all kinds of therapies conducting blood outside the human body.” said Josef Bogenschütz, CEO of Xenios.

"There is an urgent medical need to reduce inflammation in patients undergoing cardiac surgery or depending on support for a diseased lung to achieve our goal of better clinical outcomes for physicians and of course for their patients." Dr. Jürgen O. Böhm, CMMO with Xenios added.

Michael Scholl, CEO of LEUKOCARE, said: “Xenios is a strong partner: its pertinent expertise in the respective markets of extracorporeal devices and the broad range of products that will benefit from the anti-inflammatory surfaces make Xenios the perfect match for our company. This collaborative project demonstrates the full range of LEUKOCARE’s capabilities from evaluating biologically active compounds to developing marketable applications and integrating them into industrial scale processes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LEUKOCARE Announces EUR 3.4 M Capital Increase
Fundraising ensures further execution of license-based business model.
Tuesday, September 03, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!